CDMO

Pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has been recognised with a Queen’s Award in the UK for the strength of its export sales.   The CDMO won a Queen’s Award for Enterprise in the category of International Trade and was recognised for the strength of its export sales which since 2010 have […]

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Everyone can benefit from sharing experiences and learning from experts and specialists outside of their workplace […]

CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. The promise of oligonucleotides making […]

Global contract development and manufacturing organisation (CDMO) ten23 health has announced an expansion to its facility in Switzerland.  The company is expanding swissfillon’s manufacturing site, a sterile filling supplier who joined ten23 in 2021.   Ten23 will expand the site with a new manufacturing building which will constitute 5,000 square metres of space over four floors. […]

Swiss pharmaceutical company Bachem has partnered with Eli Lilly on a seven-year agreement to advance the development of oligonucleotide-based drug substances.   The agreement will see the two companies contribute to global manufacturing capacity for oligonucleotide-based medicines for patients.  Through the collaboration Bachem will provide the engineering infrastructure and expertise to implement Lilly’s oligonucleotide manufacturing technology. […]

Contract development and manufacturing organisation (CMDO) Matica Biotechnology has opened a new facility for the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.  Through the facility, Matica Bio is expanding its capacity as a CDMO and is responding to the industry’s need for […]

Contract development and manufacturing organisation (CDMO) Onyx Scientific has opened a second facility in North East England, expanding its offerings.   The company’s new site doubles Onyx Scientific’s current footprint and will enable it to expand all Chemistry, Manufacturing and Controls (CMC) activities. The facility will also enable the company to introduce additional GMP facilities that […]

Quotient Sciences, the drug development and manufacturing accelerator, has acquired Arcinova, the UK-based multiservice contract development and manufacturing organisation (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide. The acquisition expands Quotient’s service portfolio and will enable […]

The new CPhI report looks ahead to a post-pandemic 2021 with pharma manufacturing capacity and payment structures shifting as new sourcing strategies emerge. It explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies. The report – which summarises expert analysis […]